Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Regenerative Medicine and Immunomodulatory Therapy: Insights From the Kidney, Heart, Brain, and Lung.

Pino CJ, Westover AJ, Johnston KA, Buffington DA, Humes HD.

Kidney Int Rep. 2018 Jan 5;3(4):771-783. doi: 10.1016/j.ekir.2017.12.012. eCollection 2018 Jul. Review.

2.

Novel Leukocyte Modulator Device Reduces the Inflammatory Response to Cardiopulmonary Bypass.

Johnston KA, Westover AJ, Rojas-Pena A, Haft JW, Toomasian JM, Johnson T, Buffington DA, Humes HD.

ASAIO J. 2019 May/Jun;65(4):401-407. doi: 10.1097/MAT.0000000000000822.

PMID:
29863627
3.

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma.

Atchison DK, Humes HD.

Clin Nephrol Case Stud. 2017 Nov 22;5:78-81. doi: 10.5414/CNCS109165. eCollection 2017.

4.

Immunomodulatory Device Therapy in a Pediatric Patient With Acute Kidney Injury and Multiorgan Dysfunction.

Selewski DT, Goldstein SL, Fraser E, Plomaritas K, Mottes T, Terrell T, Humes HD.

Kidney Int Rep. 2017 Jul 12;2(6):1259-1264. doi: 10.1016/j.ekir.2017.06.131. eCollection 2017 Nov. No abstract available.

5.

Bioengineered Renal Cell Therapy Device for Clinical Translation.

Pino CJ, Westover AJ, Buffington DA, Humes HD.

ASAIO J. 2017 May/Jun;63(3):305-315. doi: 10.1097/MAT.0000000000000485.

6.

Development of a wearable bioartificial kidney using the Bioartificial Renal Epithelial Cell System (BRECS).

Johnston KA, Westover AJ, Rojas-Pena A, Buffington DA, Pino CJ, Smith PL, Humes HD.

J Tissue Eng Regen Med. 2017 Nov;11(11):3048-3055. doi: 10.1002/term.2206. Epub 2016 Nov 18.

7.

An Immunomodulatory Device Improves Insulin Resistance in Obese Porcine Model of Metabolic Syndrome.

Westover AJ, Johnston KA, Buffington DA, Humes HD.

J Diabetes Res. 2016;2016:3486727. Epub 2016 Oct 13.

8.

Immunomodulatory Device Promotes a Shift of Circulating Monocytes to a Less Inflammatory Phenotype in Chronic Hemodialysis Patients.

Szamosfalvi B, Westover A, Buffington D, Yevzlin A, Humes HD.

ASAIO J. 2016 Sep-Oct;62(5):623-30. doi: 10.1097/MAT.0000000000000400.

PMID:
27258222
9.

Negating Tissue Contracture Improves Volume Maintenance and Longevity of In Vivo Engineered Tissues.

Lytle IF, Kozlow JH, Zhang WX, Buffington DA, Humes HD, Brown DL.

Plast Reconstr Surg. 2015 Oct;136(4):453e-60e. doi: 10.1097/PRS.0000000000001623.

PMID:
26397264
10.

A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury.

Tumlin JA, Galphin CM, Tolwani AJ, Chan MR, Vijayan A, Finkel K, Szamosfalvi B, Dev D, DaSilva JR, Astor BC, Yevzlin AS, Humes HD; SCD Investigator Group.

PLoS One. 2015 Aug 5;10(8):e0132482. doi: 10.1371/journal.pone.0132482. eCollection 2015.

11.

A bio-artificial renal epithelial cell system conveys survival advantage in a porcine model of septic shock.

Westover AJ, Buffington DA, Johnston KA, Smith PL, Pino CJ, Humes HD.

J Tissue Eng Regen Med. 2017 Mar;11(3):649-657. doi: 10.1002/term.1961. Epub 2014 Nov 25.

12.

The bioartificial kidney.

Buffington DA, Westover AJ, Johnston KA, Humes HD.

Transl Res. 2014 Apr;163(4):342-51. doi: 10.1016/j.trsl.2013.10.006. Epub 2013 Nov 5. Review.

PMID:
24269374
13.

The bioartificial kidney: current status and future promise.

Humes HD, Buffington D, Westover AJ, Roy S, Fissell WH.

Pediatr Nephrol. 2014 Mar;29(3):343-51. doi: 10.1007/s00467-013-2467-y. Epub 2013 Apr 26. Review.

PMID:
23619508
14.

Cell-based approaches for the treatment of systemic inflammation.

Pino CJ, Yevzlin AS, Lee K, Westover AJ, Smith PL, Buffington DA, Humes HD.

Nephrol Dial Transplant. 2013 Feb;28(2):296-302. doi: 10.1093/ndt/gfs503. Epub 2012 Nov 9. Review.

15.

The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study.

Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillon J, Finkel KW, DaSilva JR, Astor BC, Yevzlin AS, Humes HD.

Semin Dial. 2013 Sep-Oct;26(5):616-23. doi: 10.1111/sdi.12032. Epub 2012 Oct 29.

PMID:
23106607
16.

Cell-based strategies for the treatment of kidney dysfunction: a review.

Pino CJ, Yevzlin AS, Tumlin J, Humes HD.

Blood Purif. 2012;34(2):117-23. doi: 10.1159/000341649. Epub 2012 Oct 24. Review.

17.

Selective cytopheretic inhibitory device with regional citrate anticoagulation and portable sorbent dialysis.

Pino CJ, Farokhrani A, Lou L, Smith PL, Johnston K, Buffington DA, Humes HD.

Artif Organs. 2013 Feb;37(2):203-10. doi: 10.1111/j.1525-1594.2012.01541.x. Epub 2012 Oct 16.

18.

Substitution-free hemodiafiltration.

Lee K, Pino CJ, Humes HD.

ASAIO J. 2012 Sep-Oct;58(5):514-21. doi: 10.1097/MAT.0b013e318260c5bb. Review.

PMID:
22951895
19.

Enhanced propagation of adult human renal epithelial progenitor cells to improve cell sourcing for tissue-engineered therapeutic devices for renal diseases.

Westover AJ, Buffington DA, Humes HD.

J Tissue Eng Regen Med. 2012 Aug;6(8):589-97. doi: 10.1002/term.471. Epub 2012 Jun 4.

20.

A selective cytopheretic inhibitory device for use during cardiopulmonary bypass surgery.

Pino CJ, Lou L, Smith PL, Ding F, Pagani FD, Buffington DA, Humes HD.

Perfusion. 2012 Jul;27(4):311-9. doi: 10.1177/0267659112444944. Epub 2012 Apr 16.

PMID:
22508804
21.

Bioartificial Renal Epithelial Cell System (BRECS): A Compact, Cryopreservable Extracorporeal Renal Replacement Device.

Buffington DA, Pino CJ, Chen L, Westover AJ, Hageman G, Humes HD.

Cell Med. 2012 Jan;4(1):33-43.

22.

A biomimetic membrane device that modulates the excessive inflammatory response to sepsis.

Ding F, Song JH, Jung JY, Lou L, Wang M, Charles L, Westover A, Smith PL, Pino CJ, Buffington DA, Humes HD.

PLoS One. 2011 Apr 14;6(4):e18584. doi: 10.1371/journal.pone.0018584.

23.

The effects of a novel therapeutic device on acute kidney injury outcomes in the intensive care unit: a pilot study.

Ding F, Yevzlin AS, Xu ZY, Zhou Y, Xie QH, Liu JF, Zheng Y, DaSilva JR, Humes HD.

ASAIO J. 2011 Sep-Oct;57(5):426-32. doi: 10.1097/MAT.0b013e31820a1494.

PMID:
21317636
24.

Cell therapy, advanced materials, and new approaches to acute kidney injury.

Yevzlin AS, Humes HD.

Hosp Pract (1995). 2009 Dec;37(1):137-43. doi: 10.3810/hp.2009.12.267. Review.

25.

Stem cell technology for the treatment of acute and chronic renal failure.

Pino CJ, Humes HD.

Transl Res. 2010 Sep;156(3):161-8. doi: 10.1016/j.trsl.2010.07.005. Epub 2010 Jul 30. Review.

26.

A microfluidic bioreactor with integrated transepithelial electrical resistance (TEER) measurement electrodes for evaluation of renal epithelial cells.

Ferrell N, Desai RR, Fleischman AJ, Roy S, Humes HD, Fissell WH.

Biotechnol Bioeng. 2010 Nov 1;107(4):707-16. doi: 10.1002/bit.22835.

27.

A selective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure.

Humes HD, Sobota JT, Ding F, Song JH; RAD Investigator Group.

Blood Purif. 2010;29(2):183-90. doi: 10.1159/000245645. Epub 2010 Jan 8.

PMID:
20093825
28.

Renal cell therapy and beyond.

Song JH, Humes HD.

Semin Dial. 2009 Nov-Dec;22(6):603-9. doi: 10.1111/j.1525-139X.2009.00663.x. Review.

29.

New insights into mechanisms of glomerular permselectivity.

Fissell WH, Humes HD.

Minerva Urol Nefrol. 2009 Dec;61(4):397-410. Review.

PMID:
19816392
30.

The bioartificial kidney in the treatment of acute kidney injury.

Song JH, Humes HD.

Curr Drug Targets. 2009 Dec;10(12):1227-34. Review.

31.

Cell therapy in kidney failure.

Humes HD, Funke AJ, Buffington DA.

Cytotechnology. 1998 Nov;28(1-3):1-8. doi: 10.1023/A:1008054723518.

32.

Dialysis dosing in critically ill patients with acute kidney injury.

Humes HD, Ding F, Song JH.

Am J Kidney Dis. 2008 Oct;52(4):649-52. doi: 10.1053/j.ajkd.2008.07.033. No abstract available.

PMID:
18805346
33.

The bioartificial kidney and bioengineered membranes in acute kidney injury.

Ding F, Humes HD.

Nephron Exp Nephrol. 2008;109(4):e118-22. doi: 10.1159/000142936. Epub 2008 Sep 18. Review.

PMID:
18802374
34.

Efficacy and safety of renal tubule cell therapy for acute renal failure.

Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, Szerlip HM, Ye J, Paganini EP, Dworkin L, Finkel KW, Kraus MA, Humes HD.

J Am Soc Nephrol. 2008 May;19(5):1034-40. doi: 10.1681/ASN.2007080895. Epub 2008 Feb 13.

35.

Development of continuous implantable renal replacement: past and future.

Fissell WH, Fleischman AJ, Humes HD, Roy S.

Transl Res. 2007 Dec;150(6):327-36. Epub 2007 Jul 2. Review.

PMID:
18022594
36.

Tissue engineering of an implantable bioartificial hemofilter.

Tiranathanagul K, Dhawan V, Lytle IF, Zhang W, Borschel GH, Buffington DA, Tziampazis E, Brown DL, Humes HD.

ASAIO J. 2007 Mar-Apr;53(2):176-86.

PMID:
17413558
37.

Dialysis and nanotechnology: now, 10 years, or never?

Fissell WH, Humes HD, Fleischman AJ, Roy S.

Blood Purif. 2007;25(1):12-7. Epub 2006 Dec 14.

PMID:
17170531
38.

Kidney epithelial cells.

Smith PL, Buffington DA, Humes HD.

Methods Enzymol. 2006;419:194-207. Review.

PMID:
17141057
39.

Bioartificial kidney in the treatment of acute renal failure associated with sepsis.

Tiranathanagul K, Brodie J, Humes HD.

Nephrology (Carlton). 2006 Aug;11(4):285-91. Review.

40.

Differentiated growth of human renal tubule cells on thin-film and nanostructured materials.

Fissell WH, Manley S, Westover A, Humes HD, Fleischman AJ, Roy S.

ASAIO J. 2006 May-Jun;52(3):221-7.

PMID:
16760708
41.

The future of hemodialysis membranes.

Humes HD, Fissell WH, Tiranathanagul K.

Kidney Int. 2006 Apr;69(7):1115-9.

42.

Stem cells: the next therapeutic frontier.

Humes HD.

Trans Am Clin Climatol Assoc. 2005;116:167-83; discussion 183-4.

43.

Stem cell approaches for the treatment of renal failure.

Brodie JC, Humes HD.

Pharmacol Rev. 2005 Sep;57(3):299-313. Review.

PMID:
16109837
44.

Translational medicine and the National Institutes of Health road map: steep grades and tortuous curves.

Humes HD.

J Lab Clin Med. 2005 Aug;146(2):51-4. No abstract available.

PMID:
16099234
45.

The future of renal support: high-flux dialysis to bioartificial kidneys.

Tiranathanagul K, Eiam-Ong S, Humes HD.

Crit Care Clin. 2005 Apr;21(2):379-94. Review.

PMID:
15781170
46.

Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.

Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER.

Am J Med. 2004 Dec 15;117(12):938-47.

PMID:
15629733
47.

Rare incorporation of bone marrow-derived cells into kidney after folic acid-induced injury.

Szczypka MS, Westover AJ, Clouthier SG, Ferrara JL, Humes HD.

Stem Cells. 2005;23(1):44-54.

48.

Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure.

Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP, Luderer JR, Sobota J.

Kidney Int. 2004 Oct;66(4):1578-88.

49.

BKV and SV40 infection of human kidney tubular epithelial cells in vitro.

Low J, Humes HD, Szczypka M, Imperiale M.

Virology. 2004 Jun 1;323(2):182-8.

50.

Advances in cell therapy for renal failure.

Humes HD, Szczypka MS.

Transpl Immunol. 2004 Apr;12(3-4):219-27. Review.

PMID:
15157916

Supplemental Content

Loading ...
Support Center